Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy.
Hirade K, Tanaka N, Kajino T, Adachi Y, Kimura R, Kasuya H, Kisoda S, Tan TK, Hayakawa S, Sato T, Yanase S, Kitaura Y, Yamamoto T, Nishioka Y, Muto O, Muraoka D, Fujishita T, Kasuga N, Watanabe K, Sakata Y, Aoki M, Matsushita H, Sanda T, Iida S, Tsuchiya K, Yamaguchi R, Ebi H.
Hirade K, et al. Among authors: kasuya h.
Cell Rep Med. 2025 Sep 16;6(9):102317. doi: 10.1016/j.xcrm.2025.102317. Epub 2025 Aug 29.
Cell Rep Med. 2025.
PMID: 40885190
Free PMC article.